Skip to main content
logo
Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
11.65
-0.40 (-3.32%)
Sep 15, 2026, 4:00 PM EDT - Market closed

Zevra Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
136.07106.4723.6127.4610.1628.65
Revenue Growth
119.40%350.92%-14.02%170.26%-64.53%115.61%
Gross Profit
129.8989.9916.225.299.9426.59
Operating Income
39.07-4.23-87-49.6-24.97.73
Net Income
57.2577.59-105.51-46.05-26.77-62.9
Earnings Per Share
0.961.35-2.28-1.30-0.78-2.11
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
221.57191.0169.567.7482.85112.35
Total Debt
1.563.2160.343.7714.131.61
Net Cash (Debt)
220.07127.819.223.9768.72110.74
Net Cash Growth
56.82%1289.18%-61.62%-65.11%-37.95%-
Net Cash Per Share
3.692.230.200.681.993.72

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
33.4-1.6-69.67-33.54-18.7210.44
Capital Expenditures
-0.78-0.84--0.3-0.09-0.1
Free Cash Flow
32.62-2.43-69.67-33.83-18.8110.34
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
95.46%84.52%68.59%92.09%97.81%92.81%
Operating Margin
28.71%-3.98%-368.47%-180.63%-245.07%26.98%
Pretax Margin
50.92%81.41%-381.76%-167.69%-263.80%-29.74%
Profit Margin
42.07%72.87%-446.85%-167.69%-263.48%-219.54%
FCF Margin
23.98%-2.28%-295.04%-123.20%-185.12%36.08%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
12.136.50----
Forward PE
13.6519.15102.50102.50102.5024.17
P/FCF Ratio
21.21----29.76
PS Ratio
5.084.7418.859.9015.5910.74